Sirnaomics Ltd. will present its preclinical and clinical development of its GalAhead™ technology-based programs, focusing on an innovative dual-targeted-GalNAc design, muRNA platform drug candidates, at the upcoming 2024 OPT Congress, which took place in Boston, USA from March 13-14, 2024.
MaaT Pharma will present extended results from its Early Access Program for patients with aGvHD that were treated with MaaT013 and, for the first time, Overall Survival data after 12 months in more patients.
Casio Computer Co., Ltd. announced that the DZ-C100 COLPOCAMERA, which is designed for uterocervical observation and photography in gynecological settings, and the CST-100M camera stand are released in the US, Australia and New Zealand.
Cognition Therapeutics, Inc. announced that it has priced an underwritten public offering of 6,571,428 shares of its common stock at an offering price of $1.75 per share of common stock.
Belite Bio, Inc announced its audited financial results for full-year 2023 and the unaudited and unreviewed financial results for the quarter ended December 31, 2023, and provided a business update.
Everest Medicines’s licensing partner Calliditas Therapeutics AB announced that the U.S. FDA has granted an orphan drug exclusivity period of seven years for Nefecon®, expiring in December 2030 based on Calliditas obtaining full approval with a new indication for this drug product in December 2023.
Innovent Biologics, Inc. announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates from its oncology pipeline will be presented at the American Association for Cancer Research Annual Meeting 2024.
Rigaku, a global solution partner in X-ray-analysis proudly announces the opening of its new Rigaku Taiwan Branch.
Rigaku Opens Taiwan Branch to Enhance Collaboration and Innovation Read More »
Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through iPSC technology, announced today that it has been accredited for ISO 9001:2015 certification.
Alkermes spun off its oncology business in late 2023 to become a pure-play neuroscience company, while Jazz Pharmaceuticals continues to invest in and focus on both of its businesses.
Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios Read More »
